Aura Biosciences, Inc. Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent
Aura Biosciences, Inc. (AURA) reported Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent of -33.10% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance · last filed 2026-03-30
- Aura Biosciences, Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, percent for fiscal 2025 was -33.10%.
- Aura Biosciences, Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, percent for fiscal 2024 was -22.60%.
- Aura Biosciences, Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, percent for fiscal 2023 was -28.80%.
- Aura Biosciences, Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, percent for fiscal 2022 was -28.50%.
| Period end | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent 12 month | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | -33.10% 10-K · filed 2026-03-30 | |
| 2024-12-31 | -22.60% 10-K · filed 2026-03-30 | -27.50% 10-K · filed 2025-03-24 |
| 2023-12-31 | -28.80% 10-K · filed 2025-03-24 | |
| 2022-12-31 | -28.50% 10-K · filed 2024-03-27 | |
| 2021-12-31 | -28.20% 10-K · filed 2023-03-15 | |
| 2020-12-31 | -29.50% 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |